Assyro AI

FDA Orange Book · active-ingredient family

Linezolid

Linezolid is approved as 4 brand and 25 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

4

Brand (NDA)

25

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · for suspension, solution, tablet

ProductApplicantApplicationTEApproved
LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERRLDHOSPIRANDA 206473Jun 18, 2015
ZYVOXRLDPFIZERNDA 021132ABApr 18, 2000
ZYVOXRLD×3PFIZERNDA 021131APApr 18, 2000
ZYVOXRLD×2PFIZERNDA 021130Apr 18, 2000

Generic (ANDA) products (25)

ProductApplicantApplicationTEApproved
LINEZOLIDCAPLINANDA 219558APDec 08, 2025
LINEZOLIDMACLEODS PHARMS LTDANDA 210378Oct 10, 2024
LINEZOLIDHETERO LABSANDA 211813ABOct 31, 2022
LINEZOLIDHIKMAANDA 206454APAug 22, 2022
LINEZOLIDCHARTWELL RXANDA 210702ABApr 25, 2019
LINEZOLID×2PHARMOBEDIENTANDA 205154APDec 06, 2017
LINEZOLID×2HQ SPCLT PHARMAANDA 207001APJul 07, 2017
LINEZOLID×2SAGENT PHARMS INCANDA 204696APMar 02, 2017
LINEZOLIDZYDUS PHARMSANDA 206097ABFeb 22, 2017
LINEZOLID×2NANG KUANG PHARM COANDA 207354APDec 20, 2016
LINEZOLIDNOVEL LABS INCANDA 207526ABAug 22, 2016
LINEZOLIDEUGIA PHARMAANDA 206917APAug 04, 2016
LINEZOLIDFRESENIUS KABI USAANDA 204764APMar 15, 2016
LINEZOLIDGATE PHARMSANDA 091210Feb 05, 2016
LINEZOLIDALEMBICANDA 205233ABDec 21, 2015
LINEZOLIDALKEM LABS LTDANDA 205517ABDec 21, 2015
LINEZOLIDAMNEAL PHARMSANDA 204536Dec 21, 2015
LINEZOLIDGLENMARK SPECLTANDA 078987ABDec 21, 2015
LINEZOLIDHETERO LABS LTD VANDA 204239ABDec 21, 2015
LINEZOLIDRISINGANDA 078845ABDec 21, 2015
LINEZOLID×2SANDOZANDA 200904APJul 16, 2015
LINEZOLIDHOSPIRAANDA 205442Jul 07, 2015
LINEZOLIDHIKMAANDA 200068ABJun 03, 2015
LINEZOLIDTEVA PHARMS USAANDA 078061May 18, 2015
LINEZOLIDTEVA PHARMSANDA 200222Jun 27, 2012

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Linezolid — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.